Australia markets close in 3 hours 43 minutes

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.1600+0.0600 (+1.94%)
At close: 04:00PM EDT
3.1500 -0.01 (-0.32%)
After hours: 07:52PM EDT

Allogene Therapeutics, Inc.

210 East Grand Avenue
South San Francisco, CA 94080
United States
650 457 2700

Full-time employees359

Key executives

NameTitlePayExercisedYear born
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.Co-Founder & Exec. Chairman714.25kN/A1949
Dr. David D. Chang M.D., Ph.D.Co-Founder, Pres, CEO & Director1.1MN/A1960
Mr. Joshua A. KazamCo-Founder & Director711kN/A1977
Yinlin ChenSr. VP of Fin.N/AN/AN/A
Mr. Timothy L. Moore Ph.D.Exec. VP & Chief Technical OfficerN/AN/A1961
Mr. Earl M. Douglas Esq.Gen. Counsel & Compliance OfficerN/AN/A1963
Ms. Susan R. LundeenChief People OfficerN/AN/A1966
Ms. Christine CassianoExec. VP, Chief Corp. Affairs & Brand Strategy OfficerN/AN/AN/A
Dr. Zachary J. Roberts M.D., Ph.D.Exec. VP of R&D and Chief Medical OfficerN/AN/A1978
Mr. David M. Tanen J.D.Sec.N/AN/A1971
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Corporate governance

Allogene Therapeutics, Inc.’s ISS governance QualityScore as of 1 October 2023 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.